Membranoproliferative Glomerulonephritis

Membranoproliferative Glomerulonephritis

No Results

No Results


Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of chronic nephritis that occurs primarily in children and young adults. This entity refers to a pattern of glomerular injury based on the following three characteristic histopathologic findings:

MPGN may be idiopathic or secondary in etiology. The secondary types are more common than the idiopathic types and are diagnosed by carefully reviewing clinical features, laboratory data, and renal histopathology. Idiopathic MPGNs are subdivided into types I, II, and III based on ultrastructural appearance. The types are characterized by the following:

The light microscopy features are mostly indistinguishable among the three types.

An alternative classification system has been proposed based on pathogenetic mechanism, as follows [1] :

Clinical presentations are similar for the three types of MPGN, but they manifest somewhat different mechanisms of complement activation and predisposition to recur in renal transplants. [2]

Conversion from one type to another is not reported. Familial forms of all 3 types of MPGN have been described.

See also Pediatric Nephritis, Tubulointerstitial Nephritis, and Radiation Nephritis.

The normal complement system consists of the classic and alternative pathways. The classic pathway is activated by the interaction of C1 with an antigen-antibody complex. This interaction results in the formation of C4b2a, which is the classic pathway C3b convertase. The alternative pathway utilizes C3 and factors B and D to form the alternative pathway convertase C3b,Bb.

Small amounts of C3b are constantly being formed in the circulation, which are inactivated by factors H and I. The binding of C3b to a foreign antigen decreases its affinity for factor H and allows for the formation of increasing amounts of the alternate pathway convertase. The classic and alternate pathway convertases cause C3 activation, forming C3a and C3b. C3b is an opsonin itself, and C3 convertase facilitates the activation of the terminal pathway and the formation of the membrane attack complex C5b-9.

Hypocomplementemia is a characteristic finding with all types of membranoproliferative glomerulonephritis (MPGN). Low C3 levels are present in approximately 75% of patients with this condition. Although hypocomplementemia bears no relation to the clinical course or prognosis of MPGN, it plays a role in initiating glomerular inflammation and injury. Hypocomplementemia results from increased catabolism and decreased C3 synthesis. The decreased C3 synthesis is likely caused by the negative feedback by C3 breakdown products.

Three nephritic antibodies are described in MPGN that play a role in the development of hypocomplementemia [3, 4] : (1) nephritic factor of the classic pathway (NFc or C4NeF), (2) nephritic factor of the amplification loop (NFa or C3NeF), and (3) nephritic factor of the terminal pathway (NFt).

The reason for genesis of nephritic antibodies is not known. These autoantibodies are not specific for MPGN and are also seen in poststreptococcal and lupus glomerulonephritis. NFc stabilizes the classic pathway C3 convertase C4b,2a. This nephritic factor does not cause C3 conversion unless C4b,2a production is ongoing. NFa (C3NEF) is an autoantibody to C3b,Bb. The binding of NFa to C3b,Bb stabilizes the complex, preventing degradation by its normal inactivators, resulting in complement activation and chronic consumption of C3.

NFt stabilizes the alternative pathway properdin-dependent C3/C5 convertase (C3Bb2,Bb,P) and leads to C3 activation and consumption. The consumption of C3 caused by NFt is much slower than that caused by NFa. NFt also activates the terminal complement components forming C5b-C9, the membrane attack complex.

Circulating immune complexes are present in approximately 33% of patients with MPGN type I. In all patients with type I disease, immune complexes are found in the mesangium and subendothelial spaces, and they trigger complement activation and the release of cytokines and chemokines. The release of inflammatory mediators causes an influx of inflammatory cells and leads to mesangial and endothelial cell proliferation. Most patients with circulating immune complexes do not develop MPGN; thus, additional pathogenic factors (eg, nature of the antigen, size of complexes, type and charge on antibodies, local glomerular factors) must play a role.

In addition to circulating immune complexes becoming entrapped in the glomerular basement membrane (GBM), experimental evidence indicates that complexes may be formed in situ when antigens adhere to the GBM, and antibodies subsequently bind to these antigens. Formation of such immune complexes triggers the same cascade as described above.

Activation of complement and the resulting hypocomplementemia may cause defective clearance of circulating immune complexes. The nephritic factor of the classic pathway (ie, NFc or C4NeF) is found in approximately 15% of patients. This nephritic factor stabilizes the classic pathway C3 convertase C4b,2a and potentiates C3 activation and consumption. The role of this nephritic factor in the pathogenesis of MPGN type I is unclear. Approximately 20% of patients have the nephritic factor of the terminal pathway.

MPGN type II, or dense deposit disease, is a separate entity that has been conventionally classified with MPGN because of the similarities of light microscopic appearance. The pathogenesis of MPGN type II is not known.

This disease is systemic, as evidenced by dense deposits in the kidney, splenic sinusoids, Bruch membrane of the retina, as well as its association with acquired partial lipodystrophy. [5, 6] MPGN type II also has a high incidence of recurrence in renal allografts. The chemical composition and origin of the dense deposits are not known, although bright staining with thioflavine-T and wheat germ agglutinin suggests the presence of N-acetyl-glucosamine. No circulating immune complexes are observed in MPGN type II.

Dense deposit disease is associated with multiple complement abnormalities, including a persistent reduction of C3 levels. One hypothesis is that the dense deposits cause complement activation. [7] This hypothesis is supported by the tram-track distribution of C3 deposits along the basement membrane.

NFa is present in 80% of patients with dense deposit disease. NFa stabilizes the alternative pathway convertase and results in complement activation and chronic C3 consumption. Deficiency of factor H, functionally defective factor H, mutant factor H binding site of C3 (Marder disease), and presence of inhibitory or blocking factor H antibodies, described in MPGN, may lead to an accumulation of the alternative pathway convertase and chronic C3 consumption.

Partial lipoid dystrophy (PLD) is associated commonly with MPGN type II and the presence of NFa. Adipocytes produce adipsin, which is identical to complement factor D and is responsible for activating the preconvertase C3b,Bb. NFa causes a lysis of adipocytes that produce adipsin, and the distribution of fat atrophy in partial lipoid dystrophy follows variations in the amount of adipsin produced by adipocytes. By analogy, NFa may cause damage to glomerular cells that produce complement.

The glomerular deposits contain C3, C5, and properdin, indicating activation of the alternative complement pathway. Signs of activation of the classic pathway are minimal, and circulating immune complexes do not appear to play a role in the genesis of this variant.

Changes in the capillary wall are hypothesized to be the primary event leading to activation of the complement pathway. This hypothesis is supported by the deposition of C3Bb2,Bbconvertase components in the basement membrane. The deposits of convertase and membrane attack complex may lyse the basement membrane and stimulate new membrane formation. NFt is present in 60-80% of patients with MPGN type III. NFt stabilizes the alternative pathway properdin-dependent C3/C5 convertase (C3Bb2,Bb,P) and also activates the terminal complement components, forming C5b-C9 (ie, the membrane attack complex).

A familial form of MPGN type III with an autosomal dominant pattern of inheritance has been identified with genetic linkage to band 1q31-32. [8] Genes in this area of chromosome 1 code for proteins that regulate the C3 convertase activity.

C3 glomerulonephritis  [9]

C3 glomerulonephritis is a recently described entity with immunofluorescence findings of isolated glomerular C3 deposits. C3 glomerulonephritis is similar in etiology to dense deposit disease, arising as a result of alternate complement activation or mutations in the complement-regulating proteins. C3NeF is commonly present. C3 glomerulonephritis has been associated with antifactor H activity and monoclonal gammopathies. Serum C3 levels are usually low, but they can be normal along with normal C4 levels. [10] It is important to note that a normal serum C3 level does not exclude C3 glomerulonephritis. Dense deposit disease and C3GN both lack immunoglobulin staining on immunofluorescence and are the result of alternative pathway dysregulation. [11] These 2 entities are often referred to as C3 glomerulopathy in literature.

Immune complex–mediated conditions, autoimmune diseases, chronic infections, chronic and recovered thrombotic microangiopathies, paraprotein deposition diseases, and malignant neoplasms associated with a membranoproliferative pattern of injury are summarized below.


In the past, most patients were thought to have idiopathic membranoproliferative glomerulonephritis (MPGN). With the discovery of secondary causes, especially hepatitis C, the number of patients deemed to have idiopathic MPGN has declined.

Autoimmune diseases

Autoimmune diseases associated with a membranoproliferative pattern of renal injury include the following:

Chronic infections

Chronic viral, bacterial, protozoal, and mycoplasmal infections, as well as chronic liver disease (cirrhosis and alpha1-antitrypsin deficiency), are associated with a membranoproliferative pattern of renal injury, as follows:

Viral – Hepatitis B, hepatitis C, [12] cryoglobulinemia type II

Bacterial – Endocarditis, infected ventriculoatrial (or jugular) shunt, multiple visceral abscesses, leprosy

Protozoal – Malaria, schistosomiasis

The following are chronic and recovered thrombotic microangiopathies associated with a membranoproliferative pattern of renal injury [13] :

Healing phase of hemolytic uremic syndrome (HUS) and/or thrombotic thrombocytopenic purpura (TTP)

Syndromes of circulating antiphospholipid (anticardiolipin) antibodies

Radiation nephritis

Nephropathy associated with bone marrow transplantation

Sickle cell anemia and polycythemia

Transplant glomerulopathy

Paraprotein deposition diseases that are associated with a membranoproliferative pattern of renal injury include the following:

Glomerulonephropathies associated with cryoglobulinemia type I

Waldenström macroglobulinemia

Immunotactoid glomerulopathy

Immunoglobulin light-chain or heavy-chain deposition diseases

Fibrillary glomerulonephritis

Monoclonal gammopathy of unknown significance

Lymphoma, leukemia, and carcinoma are associated with a membranoproliferative pattern of renal injury.

Membranoproliferative glomerulonephritis (MPGN) is observed in 6-12% of US patients receiving renal biopsies to evaluate glomerular diseases. This entity accounts for 7% of children and 12% of adults with idiopathic nephrotic syndrome.

Globally, MPGN causes a significant proportion of the cases of nephritis among patients in nonindustrialized countries. For example, in Mexico, MPGN accounts for 40% of all patients with nephritis. Most of these patients have type I disease; MPGN type II is uncommon. However, the incidence of MPGN type I is decreasing progressively in developed countries, which may be explained by a change in environmental factors, especially a decline in infections.

In an investigation of the changing patterns of adult primary glomerular disease occurrence in a single region of the United Kingdom, Hanko et al analyzed the results of 1844 native renal biopsies taken between 1976 and 2005 (inclusive) and found the presence of primary glomerulonephritis was revealed in 49% of the biopsies, with the most common forms being immunoglobulin A (IgA) nephropathy (38.8%). [14] Other common forms were membranous nephropathy (29.4%), minimal-change disease (MCD) (9.8%), MPGN type 1 (9.6%), and focal segmental glomerulosclerosis (FSGS) (5.7%). The incidence of IgA nephropathy increased significantly over the study period, whereas the occurrence of membranous nephropathy decreased. [14]

In the United States, MPGN predominantly affects the white population. Type I disease affects women more often than men, whereas a nearly equal sex distribution is seen in MPGN type II.

The idiopathic forms of MPGN are more common in children and young adults (range, 6-30 y). Isolated reports of involvement in patients as young as 2 years and as old as 80 years are noted in the literature. Secondary types of MPGN predominate among adults. [15]

The main predictors of an adverse outcome in membranoproliferative glomerulonephritis (MPGN) are nephrotic syndrome and hypertension at presentation, low glomerular filtration rate (GFR) at 1 year, and older age. [16, 17] Histologic characteristics of crescent formation, interstitial fibrosis, tubular atrophy, and multiple sclerotic glomeruli indicate a poor prognosis. However, hypocomplementemia is not a predictor of disease severity or prognosis.

MPGN type I with nephrotic syndrome is a progressive disease, with 50% of patients developing end-stage renal disease (ESRD) after 10 years and 90% of patients developing ESRD after 20 years. MPGN type I without nephrotic proteinuria has a 10-year renal survival rate of 85%. [18]

MPGN type II is generally more aggressive than type I disease and has a median renal survival rate of 5-12 years. ESRD develops in 50% of the patients within 10 years of diagnosis. C3 glomerulonephritis, on the other hand, has been associated with preserved renal function in about 50% of patients, whereas approximately 15% of patients progress to ESRD. [1]

Data on outcomes with MPGN type III are very limited. Iitaka et al found that 7 patients who were followed for 9-17 years maintained their renal function over this period, [19] whereas Anders et al reported that 4 of 8 patients in their series developed ESRD. [20] In a study comparing therapy with alternate-day corticosteroids in 21 patients with type I disease and 25 patients with type III disease (followed for a minimum of 5 y), the investigators found that patients with MPGN type III had a greater decline in GFR, but there was no difference in the number of patients reaching ESRD in the 2 groups. [21]

Kawasaki et al reported worse prognosis in pediatric patients with MPGN related to complement component C3 than in those with immune complex–mediated MPGN. In their study of 37 patients, those with C3-related MPGN were more likely to be nonresponsive to therapy or progress to ESRD. [22]

Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med. 2012 Mar 22. 366(12):1119-31. [Medline].

Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int. 2010 Apr. 77(8):721-8. [Medline].

Appel GB. Membranoprolferative glomerulonephritis – mechanisms and treatment. Contrib Nephrol. 2013. 181:163-74. [Medline].

Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens. 2005 Jul. 14(4):396-403. [Medline].

Varade WS, Forristal J, West CD. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. Am J Kidney Dis. 1990 Sep. 16(3):196-206. [Medline].

Levy Y, George J, Yona E, et al. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res. 1998 Aug. 18(1):55-60. [Medline].

Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. 2007 May. 16(3):204-12. [Medline].

Licht C, Schlötzer-Schrehardt U, Kirschfink M, et al. MPGN II–genetically determined by defective complement regulation?. Pediatr Nephrol. 2007 Jan. 22(1):2-9. [Medline].

Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012 Aug. 82(4):465-73. [Medline].

Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012 Mar. 81(5):434-41. [Medline].

Nargund P, Kambham N, Mehta K, Lafayette RA. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Clin Nephrol. 2015 Dec. 84 (12):323-30. [Medline].

Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol. 2002 Aug. 13(8):2052-7. [Medline].

Izzedine H, Sene D, Cacoub P, et al. Kidney diseases in HIV/HCV-co-infected patients. AIDS. 2009 Jun 19. 23(10):1219-26. [Medline].

Hiramatsu R, Hoshino J, Suwabe T, Sumida K, Hasegawa E, Yamanouchi M, et al. Membranoproliferative glomerulonephritis and circulating cryoglobulins. Clin Exp Nephrol. 2013 May 31. [Medline].

Tang SC, Lai KN. Hepatitis C virus-associated glomerulonephritis. Contrib Nephrol. 2013. 181:194-206. [Medline].

Cansick JC, Lennon R, Cummins CL, et al. Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis. Nephrol Dial Transplant. 2004 Nov. 19(11):2769-77. [Medline].

Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med. 1983 Feb. 74(2):175-92. [Medline].

O’Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA. Nephrol Dial Transplant. 2015 Nov 25. [Medline].

Iitaka K, Moriya S, Nakamura S, et al. Long-term follow-up of type III membranoproliferative glomerulonephritis in children. Pediatr Nephrol. 2002 May. 17(5):373-8. [Medline].

Anders D, Agricola B, Sippel M, et al. Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch A Pathol Anat Histol. 1977 Oct 27. 376(1):1-19. [Medline].

Braun MC, West CD, Strife CF. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis. 1999 Dec. 34(6):1022-32. [Medline].

Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M, et al. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol. 2016 Jul. 31 (7):1091-9. [Medline].

Masai R, Wakui H, Komatsuda A, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. 2009 Jul. 72(1):46-54. [Medline].

Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009 Sep. 20(9):2055-64. [Medline]. [Full Text].

D’Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis. 1995 Mar. 25(3):361-9. [Medline].

Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999 Mar. 106(3):347-54. [Medline].

Kidney Disease Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at Accessed: May 28, 2013.

Arikan H, Koc M, Cakalagaoglu F, et al. Histopathological changes and tumour necrosis factor-alpha, transforming growth factor-beta and tenascin expression in patients with primary type I membranoproliferative glomerulonephritis in remission. Nephrology (Carlton). 2009 Apr. 14(2):219-26. [Medline].

Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int. 1997 Oct. 52(4):871-85. [Medline].

Jones G, Juszczak M, Kingdon E, et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant. 2004 Dec. 19(12):3160-4. [Medline].

Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007 Sep. 18(9):2447-56. [Medline].

Tarshish P, Bernstein J, Tobin JN, et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone–a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992 Mar. 6(2):123-30. [Medline].

Harmankaya O, Basturk T, Ozturk Y, Karabiber N, Obek A. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol. 2001. 33(3):583-7. [Medline].

Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994. 67(1):59-65. [Medline].

Cattran DC, Cardella CJ, Roscoe JM, et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985 Feb. 27(2):436-41. [Medline].

Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003 Aug. 18(8):1573-80. [Medline].

Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med. 2008 Jan. 11(1):26-9. [Medline].

Bhat P, Weiss S, Appel GB, Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis. 2007 Oct. 50(4):641-4. [Medline].

Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol. 2009 Jan. 5(1):54-8. [Medline].

Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011 Jul. 6(7):1609-16. [Medline].

Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol. 2012 Apr. 77(4):290-5. [Medline].

Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994 Mar 17. 330(11):751-6. [Medline].

Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, et al. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry. Transplantation. 2015 Nov 19. [Medline].

Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005 May. 16(5):1392-403. [Medline].

Garini G, Allegri L, Vaglio A, et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med Int. 2005 Apr-Jun. 20(2):71-80. [Medline].

Hanko JB, Mullan RN, O’Rourke DM, et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant. 2009 Oct. 24(10):3050-4. [Medline].

Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, et al. Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients. Am J Kidney Dis. 2013 Jun 4. [Medline].

Skerka C, Licht C, Mengel M, et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol. 2009 Sep. 46(14):2801-7. [Medline].

Pranay Kathuria, MD, FACP, FASN, FNKF Professor of Medicine, Director, Division of Nephrology and Hypertension, Program Director of Nephrology Fellowship, University of Oklahoma School of Community Medicine

Pranay Kathuria, MD, FACP, FASN, FNKF is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Heart Association, American Society of Hypertension, American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ajay K Singh, MB, MRCP, MBA Associate Professor of Medicine, Harvard Medical School; Director of Dialysis, Renal Division, Brigham and Women’s Hospital; Director, Brigham/Falkner Dialysis Unit, Faulkner Hospital

Disclosure: Nothing to disclose.

Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

F John Gennari, MD Associate Chair for Academic Affairs, Robert F and Genevieve B Patrick Professor, Department of Medicine, University of Vermont College of Medicine

F John Gennari, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Clinical Investigation, American Society of Nephrology, International Society of Nephrology

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Martin Senitko, MD, and Sandeep Singh, MD, to the development and writing of the source article.

Membranoproliferative Glomerulonephritis

Research & References of Membranoproliferative Glomerulonephritis|A&C Accounting And Tax Services